silybin has been researched along with Cancer of Liver in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 12 (60.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, G; Chu, Y; Gu, N; Li, S; Li, T; Li, W; Liu, C; Polachi, N; Sun, H; Wang, X; Wu, J; Zhang, Y; Zhou, S | 1 |
| Ezhilarasan, D; Lakshmi, T | 1 |
| Chen, D; Chen, X; Chen, Y; Cui, T; Kabir, N; Ma, J; Mao, J; Pan, P; Yang, H; Yang, Y | 1 |
| Li, Y; Li, Z; Wang, Y; Yang, D; Zhu, C | 1 |
| Chen, S; Dong, Z; Liu, C; Zhang, W | 1 |
| Alimoghaddam, K; Ghaffari, SH; Ghasemi, R; Ghavamzadeh, A; Malehmir, M; Momeny, M; Pirouzpanah, S; Yousefi, M | 1 |
| Flaig, TW; Goyal, A; Greenlee, H; Gustafson, DL; Hansen, RJ; Jacobson, JS; Kelly, K; Ladas, E; Lee, V; Lunghofer, PJ; Narayan, R; Rodriguez, R; Siegel, AB; Tsai, WY; Wu, DP | 1 |
| Ding, M; Duan, W; Feng, W; Jin, Z; Liang, Z; Nie, Y; Wang, N; Yan, J; Yang, J; Yang, Y; Zhang, S | 1 |
| Bander, D; Jurczyk, K; Karpińska, E; Lachtara, M; Laurans, Ł; Socha, Ł; Wawrzynowicz-Syczewska, M | 1 |
| Choi, SJ; Gu, HR; Han, CJ; Jeong, JH; Kim, J; Kim, YC; Kim, YJ; Lee, JC; No, SH; Noh, GY; Park, SC; Yang, KY | 1 |
| Esmaeili, R; Ghaffari, SH; Jahanshiri, Z; Khorramizadeh, MR; Momeny, M; Nooridaloii, MR; Yekaninejad, MS; Yousefi, M | 1 |
| Agarwal, R; Chittezhath, M; Deep, G; Raina, K; Rajamanickam, S; Singh, RP | 1 |
| Fehér, J; Lengyel, G | 1 |
| Cui, W; Gu, F; Hu, KQ | 1 |
| Angeli, JP; Barbosa, F; Barcelos, GR; Mantovani, MS; Nersesyan, A; Serpeloni, JM | 1 |
| Dunnick, JK; Kissling, GE; Nyska, A; Peckham, J; Sanders, JM; Singh, B | 1 |
| Brandon-Warner, E; Eheim, AL; Foureau, DM; McKillop, IH; Schrum, LW; Walling, TL | 1 |
| Agarwal, C; Agarwal, R; Singh, RP; Tyagi, A; Varghese, L | 1 |
| Dvorák, Z; Ulrichová, J; Vrzal, R | 1 |
| Cui, W; Hu, KQ; Lah, JJ | 1 |
3 review(s) available for silybin and Cancer of Liver
| Article | Year |
|---|---|
Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.
Topics: Animals; Biological Availability; Clinical Trials as Topic; Humans; Liver Neoplasms; Signal Transduction; Silybin; Silymarin | 2016 |
A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases.
Topics: Antioxidants; Humans; Liver; Liver Neoplasms; NF-kappa B; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Resveratrol; Silybin; Silymarin | 2022 |
[Silymarin in the treatment of chronic liver diseases: past and future].
Topics: Antioxidants; Carcinoma, Hepatocellular; Chronic Disease; Colorectal Neoplasms; Fatty Liver; Fatty Liver, Alcoholic; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Liver Diseases; Liver Diseases, Alcoholic; Liver Neoplasms; Oxidative Stress; Silybin; Silymarin; Survival Analysis; Treatment Outcome | 2008 |
1 trial(s) available for silybin and Cancer of Liver
| Article | Year |
|---|---|
A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma.
Topics: Antioxidants; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Phosphatidylcholines; Silybin; Silybum marianum; Silymarin | 2014 |
16 other study(ies) available for silybin and Cancer of Liver
| Article | Year |
|---|---|
Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Self Renewal; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Kruppel-Like Factor 4; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Silybin; Silymarin; Sorafenib; STAT3 Transcription Factor | 2018 |
Co-delivery doxorubicin and silybin for anti-hepatoma via enhanced oral hepatic-targeted efficiency.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Doxorubicin; Drug Delivery Systems; Humans; Liposomes; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Silybin; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Silibinin A decreases statin‑induced PCSK9 expression in human hepatoblastoma HepG2 cells.
Topics: Atorvastatin; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Hepatoblastoma; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Promoter Regions, Genetic; Proprotein Convertase 9; RNA, Messenger; Silybin; Time Factors | 2019 |
Multitargeting and antimetastatic potentials of silibinin in human HepG-2 and PLC/PRF/5 hepatoma cells.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Genes, p53; Hep G2 Cells; Hepatitis B virus; Humans; Liver Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mutation; Silybin; Silymarin | 2013 |
Silybin-mediated inhibition of Notch signaling exerts antitumor activity in human hepatocellular carcinoma cells.
Topics: Animals; Antioxidants; Apoptosis; Calcium-Binding Proteins; Carcinoma, Hepatocellular; Caspase 3; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Disease Models, Animal; Glutathione; Humans; Intercellular Signaling Peptides and Proteins; Jagged-1 Protein; Liver Neoplasms; Male; Membrane Proteins; Mice; Mitochondria; Reactive Oxygen Species; Receptors, Notch; RNA Interference; Serrate-Jagged Proteins; Signal Transduction; Silybin; Silymarin; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Rescue therapy with intravenous silibinin in liver transplant recipients with recurrent HCV hepatitis - two case reports.
Topics: Administration, Intravenous; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Recurrence; Salvage Therapy; Silybin; Silymarin | 2014 |
Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Silybin; Silymarin; Sorafenib | 2015 |
Effects of silibinin on cell growth and invasive properties of a human hepatocellular carcinoma cell line, HepG-2, through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation.
Topics: Adaptor Proteins, Signal Transducing; Antioxidants; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Membrane Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nitric Oxide; Phosphatidylethanolamine Binding Protein; Phosphorylation; Repressor Proteins; RNA, Messenger; Silybin; Silymarin | 2008 |
Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.
Topics: Adenocarcinoma; Animals; Antioxidants; Apoptosis; Biomarkers, Tumor; Blotting, Western; Body Weight; Cell Cycle Proteins; Cell Movement; Cell Proliferation; Disease Models, Animal; Disease Progression; Female; Humans; Immunoenzyme Techniques; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Mice, Transgenic; Neoplasm Staging; Neovascularization, Pathologic; Nitric Oxide Synthase Type II; Prostate; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Silybin; Silybum marianum; Silymarin; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2008 |
Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice.
Topics: alpha-Fetoproteins; Animals; Antioxidants; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Dietary Supplements; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Histones; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Mice; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Transplantation; Proto-Oncogene Proteins c-akt; Repressor Proteins; Silybin; Silymarin; Superoxide Dismutase; Superoxide Dismutase-1; Survivin; Transplantation, Heterologous | 2009 |
Evaluation of the genotoxic and anti-genotoxic activities of silybin in human hepatoma cells (HepG2).
Topics: Aflatoxin B1; Benzo(a)pyrene; Bleomycin; Carcinoma, Hepatocellular; Cell Death; Cell Division; Cell Line, Tumor; DNA; DNA Damage; DNA-Formamidopyrimidine Glycosylase; Endonucleases; Escherichia coli Proteins; Humans; Intracellular Space; Liver Neoplasms; Micronuclei, Chromosome-Defective; Mutagens; Reactive Oxygen Species; Silybin; Silymarin | 2010 |
Investigating the potential for toxicity from long-term use of the herbal products, goldenseal and milk thistle.
Topics: Animals; Berberine; Body Weight; Carcinogens; Female; Flavonolignans; Hydrastis; Liver Neoplasms; Male; Mice; Mice, Inbred Strains; Plant Preparations; Plant Roots; Rats; Rats, Inbred F344; Silybin; Silybum marianum; Silymarin; Topoisomerase Inhibitors; Toxicity Tests, Chronic | 2011 |
Silibinin (Milk Thistle) potentiates ethanol-dependent hepatocellular carcinoma progression in male mice.
Topics: Alcohol Drinking; Animals; Antioxidants; Carcinoma, Hepatocellular; Cell Proliferation; Dietary Supplements; Disease Progression; Ethanol; Female; Liver Neoplasms; Male; Mice; Sex Characteristics; Silybin; Silybum marianum; Silymarin; Tumor Burden | 2012 |
Silibinin efficacy against human hepatocellular carcinoma.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Cyclin D1; Cyclin D3; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Flow Cytometry; Humans; Liver Neoplasms; Silybin; Silybum marianum; Silymarin; Tumor Cells, Cultured | 2005 |
Silybin and dehydrosilybin inhibit cytochrome P450 1A1 catalytic activity: a study in human keratinocytes and human hepatoma cells.
Topics: Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Survival; Cytochrome P-450 CYP1A1; Dioxins; Dose-Response Relationship, Drug; Enzyme Induction; Humans; Keratinocytes; Liver Neoplasms; Molecular Structure; Silybin; Silymarin; Time Factors | 2006 |
Effects and mechanisms of silibinin on human hepatoma cell lines.
Topics: Acetylation; Antioxidants; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Histones; Humans; Liver Neoplasms; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Signal Transduction; Silybin; Silymarin | 2007 |